With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.

Its sales of Wegovy, one of the top-selling anti-obesity medications, continue to grow rapidly. Novo Nordisk recently ...

In a video shared to TikTok via her page, @lucy52915, which has racked up more than 750,000 views, she revealed pictures of ...

NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer Former Amgen, Novo Nordisk and Boehringer Ingelheim senior leader joins NodThera Leadership TeamWill spearhead clinical ...

The joint effort will focus on providing patients with medication guidance, reminders, tracking of efficacy and health education.

You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy. This site is protected by ...

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

With their lengthening laundry list of health benefits, drugs like Ozempic and Wegovy are showing promise outside of weight loss and diabetes treatments. One of the most exciting off-label uses of ...

Novo Nordisk A/S (NYSE: NVO) is one of the high-margin pharma stocks to buy now. Berenberg has reaffirmed its Hold rating on ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

In Novo Nordisk A/S’s home country of Denmark, the popularity of weight-loss drugs is fueling economic growth, but local ...